natgillin/translations-raw huggingface dataset:
Symptoms almost always include fever or rash, but also very commonly include nausea, vomiting, diarrhoea, abdominal pain, dyspnoea (difficulty breathing), cough, fever, lethargy, malaise (feeling unwell), headache, signs of liver damage in the blood and myalgia (muscle pain).
Simptomi skoraj vedno vključujejo povišano telesno temperaturo ali izpuščaje, zelo pogosto pa tudi slabost, bruhanje, drisko, bolečine v trebuhu, dispnejo (oteženo dihanje), kašelj, povišano telesno temperaturo, letargijo, neugodje (slabo počutje), glavobol, znake obolenja jeter v krvi in mialgijo (bolečine v mišicah).
Patients treated with Ziagen receive a card detailing these symptoms so that they are aware of them, and must contact their doctor immediately if they develop a reaction.
Bolniki, ki jemljejo zdravilo Ziagen, prejmejo kartonček, na katerem so ti simptomi podrobno opisani, tako da jih lahko takoj poznajo, in se morajo takoj posvetovati s svojim zdravnikom, če se pri njih pojavijo tovrstne reakcije.
Ziagen should not be used in patients with severe liver disease or who may be hypersensitive (allergic) to abacavir or any of the other ingredients.
Zdravila Ziagen ne smejo uporabljati bolniki s hudimi obolenji jeter ali tisti, ki bi lahko bili preobčutljivi za (alergični na) abakavir ali katero koli drugo sestavino zdravila.
As with other anti-HIV medicines, patients taking Ziagen may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Kot pri drugih zdravilih proti okužbi z virusom HIV lahko pride tudi pri bolnikih, ki jemljejo zdravilo Ziagen, do lipodistrofije (spremembe v porazdelitvi telesne maščobe), osteonekroze (odmiranja kostnega tkiva) ali sindroma imunske reaktivacije (simptomov okužbe, ki jih povzroči izboljšanje stanja imunskega sistema).
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Ziagen.
Bolniki, ki imajo težave z jetri (vključno z okužbami s hepatitisom B ali C) so z jemanjem zdravila Ziagen izpostavljeni večjemu tveganju, da pride do poškodb jeter.
As with all other NRTIs, Ziagen may also cause lactic acidosis (a build-up of lactic acid in the body) and, in the babies of mothers taking Ziagen during pregnancy, mitochondrial dysfunction (damage to the energy-producing components within cells that can cause problems in the blood).
2/ 3 Ziagen, pa mitohondrijsko disfunkcijo (poškodbo komponent za proizvajanje energije v celicah, kar se lahko odraža v težavah s krvjo).
The Committee for Medicinal Products for Human Use (CHMP) decided that Ziagen’ s benefits are greater than its risks for use in antiretroviral combination therapy for the treatment of HIV-infected patients.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ziagen, kadar se uporablja kot protiretrovirusno sredstvo v kombinaciji z drugimi zdravili za zdravljenje bolnikov, okuženih s HIV, večje od z njim povezanih tveganj.
The Committee noted that the demonstration of the benefit of Ziagen was based on the results of studies mainly carried out with the medicine taken twice a day in combination with other medicines
Odbor je upošteval, da je prikaz koristi zdravila Ziagen temeljil na rezultatih študij, ki so bile v glavnem izvedene z zdravilom, ki so ga odrasli bolniki, ki pred tem niso jemali zdravil proti HIV, jemali dvakrat dnevno v kombinaciji z drugimi zdravili.
The Committee recommended that Ziagen be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Ziagen odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Ziagen to Glaxo Group Ltd on 8 July 1999.
Evropska komisija je dovoljenje za promet z zdravilom Ziagen, veljavno po vsej Evropski uniji, odobrila družbi Glaxo Group Ltd dne 8. julija 1999.
The marketing authorisation was renewed on 8 July 2004.
Dovoljenje za promet z zdravilom je bilo obnovljeno 8. julija 2004.
The full EPAR for Ziagen can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ziagen je na voljo tukaj.
The scored tablets are yellow, biconvex, capsule shaped and are engraved with GX 623 on both sides.
Rumene bikonveksne tablete v obliki kapsule z razdelilno zarezo in oznako GX 623 na obeh straneh.
Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
Zdravilo Ziagen je v kombinaciji z drugimi protiretrovirusnimi zdravili indicirano za zdravljenje bolnikov, okuženih z virusom HIV (Human Immunodefficiency Virus).
The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy (see section 5.1).
Prikaz prednosti zdravila Ziagen v glavnem temelji na rezultatih študij, ki so bile pri režimu odmerjanja dvakrat na dan izvedene pri odraslih bolnikih, ki še niso bili zdravljeni s kombinirano terapijo (glejte poglavje 5. 1).
Alternatively, for patients who are unable to swallow tablets, the tablet(s) may be crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately (see section 5.2).
Bolnik, ki tablet ne more pogoltniti, lahko tablete tudi zdrobi in jih doda v manjšo količino redke hrane ali tekočine, ki jo mora nato v celoti takoj zaužiti (glejte poglavje 5. 2).
Adults and adolescents (over 12 years of age): the recommended dose of Ziagen is 600 mg daily.
Priporočeni odmerek zdravila Ziagen znaša 600 mg na dan.
This may be administered as either 300 mg (one tablet) twice daily or 600 mg (two tablets) once daily (see sections 4.4 and 5.1).
Priporočeni odmerek se lahko jemlje kot 300 mg (ena tableta) dvakrat na dan ali kot 600 mg (dve tableti) enkrat na dan (glejte poglavji 4. 4 in 5. 1).
Patients changing to the once daily regimen should take 300 mg twice a day and switch to 600 mg once a day the following morning.
2 Bolniki, ki bodo prešli na režim odmerjanja enkrat na dan, morajo jemati 300 mg dvakrat na dan, nato pa naslednje jutro preiti na 600 mg enkrat na dan.
When changing
Če želijo, pri režimu odmerjanja enkrat na dan, jemati odmerek zvečer, morajo prvo jutro vzeti zdravilo Ziagen v odmerku 300 mg in nato zvečer 600 mg.
2 back to a twice daily regimen, patients should complete the day's treatment and start 300 mg twice a day the following morning.
Pri prehajanju nazaj na režim odmerjanja dvakrat na dan, morajo bolniki prejeti celoten dnevni odmerek in nato naslednje jutro pričeti z jemanjem 300 mg dvakrat na dan.
A dosing according to weight bands is recommended for Ziagen tablets.
Pri uporabi zdravila Ziagen v obliki tablet priporočamo odmerjanje na osnovi telesne mase.
This dosing regimen for paediatric patients weighing 14-30 kg is based primarily on pharmacokinetic modelling.
Režim odmerjanja pri otrocih s telesno maso od 14 do 30 kg temelji predvsem na podatkih farmakokinetičnega modeliranja.
A pharmacokinetic overexposure of abacavir can occur since accurate dosing can not be achieved with this formulation.
Ker s to farmacevtsko obliko ni možno zagotoviti natančnega odmerjanja, lahko pride do prevelike farmakokinetične izpostavljenosti.
Therefore a close safety monitoring is warranted in these patients.
Te bolnike je treba skrbno nadzirati glede varnosti.
Children weighing at least 30 kg: the adult dosage of 300 mg twice daily should be taken.
Otroci s telesno maso večjo od 30 kg morajo jemati odmerek za odrasle, to je 300 mg dvakrat na dan.
Children weighing > 21 kg to < 30 kg: one half of a Ziagen tablet taken in the morning and one whole tablet taken in the evening.
Otroci s telesno maso večjo od 21 kg in manjšo od 30 kg: polovica Ziagen tablete zjutraj in ena cela tableta zvečer.
Children weighing 14 to 21 kg: one half of a Ziagen tablet twice daily.
Otroci s telesno maso od 14 do 21 kg: polovica Ziagen tablete dvakrat na dan.
Children less than three months: the data available on the use of Ziagen in this age group are very limited (see section 5.2).
Podatkov o uporabi zdravila Ziagen pri tej starostni skupini je zelo malo (glejte poglavje 5. 2).
Renal impairment: no dosage adjustment of Ziagen is necessary in patients with renal dysfunction.
Za bolnike z motnjami v delovanju ledvic ni treba prilagajati odmerkov.
However, Ziagen should be avoided in patients with end-stage renal disease (see section 5.2).
Vendar pa zdravila Ziagen ne smemo dajati bolnikom v končnem stadiju ledvičnega obolenja (glejte poglavje 5. 2).
Hepatic impairment: abacavir is primarily metabolised by the liver.
Abakavir se v prvi vrsti presnavlja preko ledvic.
No dose recommendation can be made in patients with mild hepatic impairment.
Za bolnike z blago jetrno okvaro ni možno pripraviti priporočil za odmerjanje.
No data are available in patients with moderate hepatic impairment, therefore the use of abacavir is not recommended unless judged necessary.
Na voljo ni podatkov o odmerjanju pri bolnikih z zmerno jetrno okvaro, zato uporaba abakavirja ni priporočljiva, razen če je nujno potrebna.
In patients with mild and moderate hepatic impairment close monitoring is required, and if feasible, monitoring of abacavir plasma levels is recommended (see section 5.2).
Potreben je skrben nadzor.
Abacavir is contraindicated in patients with severe hepatic impairment (see section 4.3 and 4.4).
Abakavir je kontraindiciran pri bolnikih z hudo jetrno okvaro (glejte poglavje 4. 3, 4. 4 in 5. 2).
Elderly: no pharmacokinetic data is currently available in patients over 65 years of age.
Za bolnike nad 65. letom starosti trenutno nimamo farmakokinetičnih podatkov.
Ziagen is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients.
Zdravilo Ziagen je kontraindicirano pri bolnikih z znano preobčutljivostjo na zdravilno učinkovino ali katerokoli pomožno snov.
See BOXED INFORMATION ON HYPERSENSITIVITY REACTIONS in sections 4.4. and 4.8.
Glejte PODATKE O PREOBČUTLJIVOSTNIH REAKCIJAH V OKVIRU v poglavjih 4. 4 in 4. 8.
Ziagen is contraindicated in patients with severe hepatic impairment.
Zdravilo Ziagen je kontraindicirano pri bolnikih s hudo jetrno okvaro.
In clinical studies approximately 5% of subjects receiving abacavir develop a hypersensitivity reaction; some of these cases were life-threatening and resulted in a fatal outcome despite taking precautions.
V kliničnih študijah se je pri okoli 5% bolnikov, ki so jih zdravili z abakavirjem, razvila preobčutljivostna reakcija; nekateri od teh primerov so bili življenjsko nevarni in so se kljub varnostnim ukrepom končali s smrtjo.
3 These results are consistent with those of prior retrospective studies.
3 Ti rezultati so v skladu z rezultati predhodnih retrospektivnih študij.
As a consequence, before initiating treatment with abacavir, screening for carriage of the HLA- B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin.
Posledično je pred uvedbo zdravljenja z abakavirjem pri vsakem bolniku, okuženim z virusom HIV, treba opraviti presejalni test za prisotnost alela HLA- B* 5701, ne glede na rasno poreklo.
Hypersensitivity reactions are characterised by the appearance of symptoms indicating multi-organ system involvement.
Za preobčutljivostne reakcije je značilen pojav simptomov, ki kažejo na sistemsko prizadetost več organov/ sistemov.
Almost all hypersensitivity reactions will have fever and/ or rash as part of the syndrome.
Pri skoraj vseh preobčutljivostnih reakcijah kot del sindroma nastopi vročina in/ ali izpuščaj.
Other signs and symptoms may include respiratory signs and symptoms such as dyspnoea, sore throat, cough and abnormal chest x-ray findings (predominantly infiltrates, which can be localised), gastrointestinal symptoms, such as nausea, vomiting, diarrhoea, or abdominal pain, and may lead to misdiagnosis of hypersensitivity as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis.
Drugi znaki in simptomi lahko obsegajo respiratorne simptome, denimo dispnejo, bolečine v grlu ali kašelj, in nenormalnosti po rentgenskem slikanju prsnega koša (pretežno infiltrati, ki jih je možno lokalizirati), gastrointestinalne simptome, denimo navzeo, bruhanje, diarejo ali bolečine v trebuhu, in lahko privedejo do tega, da se preobčutljivost napačno diagnosticira kot respiratorna bolezen (pljučnica, bronhitis, faringitis) ali gastroenteritis.
Other frequently observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia).
Drugi pogosto opaženi znaki ali simptomi preobčutljivostne reakcije lahko vključujejo letargijo ali slabo počutje ter mišično- skeletne simptome (mialgijo, redko miolizo, artralgijo).
The symptoms related to this hypersensitivity reaction worsen with continued therapy and can be life- threatening.
Simptomi, do katerih pride zaradi te preobčutljivostne reakcije, se z nadaljevanjem zdravljenja poslabšajo in so lahko življenjsko ogrožujoči.
These symptoms usually resolve upon discontinuation of Ziagen.
Po prenehanju jemanja zdravila Ziagen simptomi navadno izginejo.
Hypersensitivity reaction symptoms usually appear within the first six weeks of initiation of treatment with abacavir, although these reactions may occur at any time during therapy.
Simptomi preobčutljivostne reakcije se navadno pojavijo v prvih šestih tednih po začetku zdravljenja z abakavirjem, čeprav se lahko ta reakcija pojavi kadarkoli med terapijo.
Patients should be monitored closely, especially during the first two months of treatment with Ziagen, with consultation every two weeks.
Bolnike moramo skrbno nadzorovati, zlasti v prvih dveh mesecih zdravljenja z zdravilom Ziagen, zdravnika pa morajo obiskati vsaka dva tedna.
Patients who are diagnosed with a hypersensitivity reaction whilst on therapy MUST discontinue Ziagen immediately.
Bolniki, pri katerih med terapijo ugotovimo preobčutljivostno reakcijo, MORAJO takoj prenehati jemati zdravilo Ziagen.
Ziagen, or any other medicinal product containing abacavir (i. e.
Bolniki, ki so zaključili zdravljenje zaradi preobčutljivostne reakcije, NE SMEJO NIKOLI VEČ jemati zdravila Ziagen ali katerega drugega zdravila, ki vsebuje abakavir (npr.
Kivexa, Trizivir), MUST NEVER be restarted in patients who have stopped therapy due to a hypersensitivity reaction.
Kivexa, Trizivir).
Restarting abacavir following a hypersensitivity reaction results in a prompt return of symptoms within hours.
Če bi začeli po preobčutljivostni reakciji znova jemati zdravilo Ziagen, bi imelo to za posledico takojšnjo povrnitev simptomov že v nekaj urah.
This recurrence is usually more severe than on initial presentation, and may include life- threatening hypotension and death.
Rekurenca je navadno še hujša kot prvi pojav preobčutljivosti in lahko povzroči življenjsko ogrožujočo hipotenzijo in smrt.
To avoid a delay in diagnosis and minimise the risk of a life-threatening hypersensitivity reaction, Ziagen must be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible (respiratory diseases, flu-like illness, gastroenteritis or reactions to other medications).
Kadar ne moremo izključiti preobčutljivosti, in da bi se izognili zamudi pri diagnosticiranju ter čimbolj zmanjšali tveganje za pojav življenjsko nevarne preobčutljivostne reakcije, moramo z
4 by these products and abacavir related hypersensitivity reactions.
4 dajanjem zdravila Ziagen trajno prenehati, čeprav bi bile možne tudi druge diagnoze (respiratorne bolezni, gripi podobna obolenja, gastroenteritis ali reakcije na druga zdravila).
• Management after an interruption of Ziagen therapy
• Ukrepi v primeru prekinitve zdravljenja z zdravilom Ziagen
If therapy with Ziagen has been discontinued for any reason and restarting therapy is under consideration, the reason for discontinuation must be established to assess whether the patient had any symptoms of a hypersensitivity reaction.
Če je bilo zdravljenje z zdravilom Ziagen iz kateregakoli razloga prekinjeno in razmišljamo o tem, da bi z njim ponovno začeli, moramo najprej ugotoviti razlog za prekinitev, da ocenimo, ali je bolnik imel simptome preobčutljivostne reakcije.
If a hypersensitivity reaction cannot be ruled out, Ziagen or any other medicinal product containing abacavir (i. e.
Če preobčutljivostne reakcije ne moremo izključiti, zdravljenja z zdravilom Ziagen ali katerimkoli drugim zdravilom, ki vsebuje abakavir (npr.
Kivexa, Trizivir) must not be restarted.
Kivexa, Trizivir), ne smemo ponoviti.
Hypersensitivity reactions with rapid onset, including life-threatening reactions have occurred after restarting Ziagen in patients who had only one of the key symptoms of hypersensitivity (skin rash, fever, gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise) prior to stopping Ziagen.
Pri bolnikih, ki so imeli pred prenehanjem jemanja zdravila Ziagen samo enega od ključnih simptomov preobčutljivosti (kožni izpuščaj, vročino, gastrointestinalne, respiratorne ali konstitucionalne simptome, kakor je letargija in slabo počutje), so po ponovnem začetku jemanja zdravila Ziagen naglo nastopile preobčutljivostne reakcije, vključno z življenjsko nevarnimi reakcijami.
The most common isolated symptom of a hypersensitivity reaction was a skin rash.
Najpogostejši izolirani simptom preobčutljivostne reakcije je bil kožni izpuščaj.
Moreover, on very rare occasions hypersensitivity reactions have been reported in patients who have restarted therapy, and who had no preceding symptoms of a hypersensitivity reaction.
Preobčutljivostne reakcije so bile v redkih primerih opažene tudi pri bolnikih, ki so znova začeli z zdravljenjem, a pred tem niso imeli nobenih simptomov preobčutljivostne reakcije.
In both cases, if a decision is made to restart Ziagen this must be done in a setting where medical assistance is readily available.
V obeh primerih velja, da če se odločite za ponovno dajanje zdravila Ziagen, storite to v okolju, kjer bo na razpolago takojšnja medicinska pomoč.
Prescribers must ensure that patients are fully informed regarding the following information on the hypersensitivity reaction:
Zdravniki, ki predpisujejo to zdravilo, morajo zagotoviti, da so bolniki v celoti seznanjeni z naslednjimi informacijami v zvezi s preobčutljivostnimi reakcijami:
- patients must be made aware of the possibility of a hypersensitivity reaction to abacavir that
- Bolniki morajo biti seznanjeni z možnostjo pojava preobčutljivostne reakcije na abakavir, ki se
may result in a life-threatening reaction or death.
lahko kaže kot življenjsko nevarna reakcija ali smrt.
- patients developing signs or symptoms possibly linked with a hypersensitivity reaction
- Bolniki, ki opazijo znake ali simptome, ki utegnejo biti povezani s preobčutljivostno reakcijo
MUST CONTACT their doctor IMMEDIATELY.
MORAJO o tem NEMUDOMA obvestiti svojega zdravnika.
- patients who are hypersensitive to abacavir should be reminded that they must never take
- Bolnike, ki so preobčutljivi na abakavir, moramo opomniti, da ne smejo nikoli več jemati
Ziagen or any other medicinal product containing abacavir (i. e.
zdravila Ziagen ali kakšnega drugega zdravila, ki vsebuje abakavir (npr.
- in order to avoid restarting Ziagen, patients who have experienced a hypersensitivity reaction
- Da bolniki, ki so doživeli preobčutljivostno reakcijo, ne bi začeli znova jemati zdravila Ziagen,
should be asked to return the remaining Ziagen tablets or oral solution to the pharmacy.
jih je treba prositi, naj neporabljene tablete zdravila Ziagen ali peroralno raztopino vrnejo v lekarno.
- patients who have stopped Ziagen for any reason, and particularly due to possible adverse
- Bolnike, ki so zaradi kateregakoli razloga prenehali jemati zdravilo Ziagen, še zlasti če se je to
reactions or illness, must be advised to contact their doctor before restarting.
zgodilo zaradi neželenega učinka ali bolezni, je treba opozoriti, da morajo pred vnovičnim začetkom jemanja obiskati svojega zdravnika.
- patients should be advised of the importance of taking Ziagen regularly.
- Bolnike je treba poučiti o pomembnosti je rednega jemanja zdravila Ziagen.
- each patient should be reminded to read the Package Leaflet included in the Ziagen pack.
- Vsakega bolnika je treba spomniti, naj prebere navodilo za uporabo, ki je priloženo škatlici
They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.
Spomniti jim je treba tudi na to, kako zelo pomembno je, da iz škatlice vzamejo opozorilno kartico in jo vedno nosijo s seboj.
Lactic acidosis: lactic acidosis, usually associated with hepatomegaly and hepatic steatosis, has been reported with the use of nucleoside analogues.
Pri uporabi nukleozidnih analogov so poročali o pojavih laktične acidoze navadno povezane s hepatomegalijo in jetrno steatozo.
Early symptoms (symptomatic hyperlactatemia) include benign digestive symptoms (nausea, vomiting and abdominal pain), non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/ or deep breathing) or neurological symptoms (including motor weakness).
5 blagi prebavni simptomi (slabost, bruhanje in bolečine v trebuhu, nespecifičen občutek neugodja, izguba teka, izguba telesne mase, respiratorni simptomi (hitro in/ ali globoko dihanje) ali nevrološki simptomi (vključno z gibalno šibkostjo).
Lactic acidosis has a high mortality and may be associated with pancreatitis, liver failure, or renal failure.
Laktacidoza ima visoko stopnjo smrtnosti in je lahko povezana s pankreatitisom, jetrnim popuščanjem ali ledvičnim popuščanjem.
Lactic acidosis generally occurred after a few or several months of treatment.
Laktacidoza navadno nastopi po nekaj ali več mesecih zdravljenja.
5 Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Zdravljenje z nukleozidnimi analogi je treba prekiniti ob pojavu simptomov hiperlaktatemije in presnovne acidoze/ laktacidoze, progresivne hepatomegalije ali hitrega porasta koncentracije aminotransferaze.
Caution should be exercised when administering nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol).
Previdnost je potrebna pri dajanju nukleozidnih analogov bolnikom (zlasti ženskam z visoko prekomerno telesno maso) s hepatomegalijo, hepatitisom ali drugimi znanimi dejavniki tveganja za jetrno bolezen in jetrno steatozo (vključno z določenimi zdravili in alkoholom).
Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Bolniki hkrati okuženi s hepatitisom C in zdravljeni z interferonom alfa in riboflavinom, lahko predstavljajo posebno rizično skupino.
Patients at increased risk should be followed closely.
Bolnike izpostavljene povišanemu tveganju je treba natančno spremljati.
Lipodystrophy: combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients.
Kombinirano protiretrovirusno zdravljenje so pri bolnikih s HIV povezali s prerazporeditvijo telesnega maščevja (lipodistrofija).
A connection between visceral lipomatosis and protease inhibitors (PIs) and lipoatrophy and nucleoside reverse transcriptase inhibitors (NRTIs) has been hypothesised.
Domneva se povezava med visceralno lipomatozo in inhibitorji proteaze (PI- ji) in lipoatrofijo in nukleozidnimi inhibitorji reverzne transkriptaze (NRTI - ji).
A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances.
Višje tveganje za lipodistrofijo je bilo povezano z individualnimi dejavniki, kot je višja starost in z dejavniki, povezanimi z zdravilom, kot je dolgotrajno protiretrovirusno zdravljenje ter s tem povezane presnovne motnje.